# A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis

> **NCT05896527** · PHASE2 · COMPLETED · sponsor: **DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company** · enrollment: 229 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** DC-806
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05896527
- **Lead sponsor:** DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-02
- **Primary completion:** 2024-03-25
- **Final completion:** 2024-03-25
- **Target enrollment:** 229 (ACTUAL)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05896527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05896527, "A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05896527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*